Orthocell Posts Record U.S. Remplir Sales in October 2026
Australian medtech firm Orthocell hit its highest U.S. monthly sales for its Remplir nerve wrap since the product launched, moving 92 units in October 2026.
Orthocell Ltd, an Australian medical device manufacturer, recorded its strongest month of U.S. sales for its Remplir collagen nerve wrap since the product first came to market, the company announced. The milestone was reached in October 2026, when 92 units of the device were sold in the United States alone.
Remplir is a collagen-based nerve wrap cleared by the U.S. Food and Drug Administration and designed to support the repair and protection of peripheral nerves. The device is engineered and produced at Orthocell's facilities in Australia, and the company has been positioning it as a category leader across key international markets.
Read more Investcorp Reports $65.2B AUM at Gateway Gulf Forum →
The October sales figure represents a notable commercial inflection point for the Perth-based firm as it competes in the peripheral nerve repair segment, a niche but growing area of the surgical device industry. Orthocell's U.S. commercial push has been central to its growth strategy, and the latest monthly result suggests that traction is building with American surgeons and health systems.
Analysts tracking the medtech sector have noted that collagen-based nerve repair products occupy a specialized but competitively contested space, with clinical adoption often hinging on surgeon familiarity and reimbursement pathways. Orthocell's FDA clearance gives Remplir a regulatory foundation to compete directly with established players in the U.S. market.
Continue reading at All Financial Services & Investing.
